4.7 Article

Cardiovascular Risk in Women With Premature Ovarian Insufficiency Compared to Premenopausal Women at Middle Age

Journal

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 101, Issue 9, Pages 3306-3315

Publisher

ENDOCRINE SOC
DOI: 10.1210/jc.2016-1141

Keywords

-

Funding

  1. Dutch Heart Foundation [2013T083]
  2. Erasmus MC
  3. Erasmus University, Rotterdam, The Netherlands
  4. Netherlands Organisation for Scientific Research (NWO)
  5. Netherlands Organisation for Health Research and Development (ZonMw)
  6. Research Institute for Diseases in the Elderly (RIDE)
  7. Ministry of Education, Culture and Science
  8. Ministry for Health, Welfare and Sports
  9. European Commission (DG XII)
  10. Municipality of Rotterdam
  11. Nestle Nutrition (Nestec Ltd.)
  12. Metagenics Inc.
  13. AXA
  14. NWO VENI [91616079]
  15. Ferring
  16. Merck-Serono
  17. Merck SharpeDome
  18. Organon
  19. Schering Plough
  20. Serono
  21. Auxogyn
  22. MSD
  23. Actavis
  24. COGI
  25. Dutch Heart Foundation
  26. Euroscreen
  27. Finox
  28. Gedeon-Richter
  29. OvaScience
  30. Pantharei Bioscience
  31. PregLem
  32. Roche
  33. Uteron
  34. Watson Laboratories

Ask authors/readers for more resources

Context: A young age at menopause has been associated with increased cardiovascular disease (CVD) risk. Objective: To compare the cardiovascular risk profile between women with premature ovarian insufficiency (POI) and premenopausal controls of comparable age. Design: Cross-sectional case control study. Setting: Two university medical centers. Participants: Women above 45 years of age who were previously diagnosed with POI (n = 83) and premenopausal population controls of comparable age (n = 266). Main Outcome Measures: Blood pressure, body mass index, waist circumference, electrocardiogram, bilateral carotid intima media thickness, estradiol, T, androstenedione, dehydroepiandrosterone sulfate, SHBG, insulin, glucose, lipids, TSH, free T-4, N-terminal pro-B-type natriuretic peptide, C-reactive protein, uric acid, creatinine, and homocysteine were measured. Potential associations between POI status and subclinical atherosclerosis were assessed. Results: Women with POI exhibited an increased waist circumference (beta = 5.7; 95% confidence interval [CI], 1.6, 9.9), C-reactive protein (beta = 0.75; 95% CI, 0.43, 1.08), free T-4 levels (beta = 1.5; 95% CI, 0.6, 2.4), and lower N-terminal pro-B-type natriuretic peptide (beta = -0.35; 95% CI, -0.62, -0.08), estradiol (beta = -1.98; 95% CI, -2.48, -1.48), T (beta = -0.21; 95% CI, -0.37, -0.06), and androstenedione (beta = -0.54; 95% CI, -0.71, -0.38) concentrations compared to controls, after adjusting for confounders. After adjustment, a trend toward increased hypertension (odds ratio -2.1; 95% CI, 0.99; 4.56) and decreased kidney function was observed in women with POI (creatinine beta = -3.5; 95% CI, -0.05, 7.1; glomerular filtration rate beta = -3.5; 95% CI, -7.5, 0.46). Women with POI exhibited a lower mean carotid intima media thickness (beta = -0.17; 95% CI, -0.21, -0.13) and decreased odds of plaque presence compared to controls (odds ratio = 0.08; 95% CI, 0.03; 0.26). Conclusions: Women with POI exhibited an unfavorable cardiovascular risk profile, including higher abdominal fat, elevated chronic inflammatory factors, and a trend toward increased hypertension and impaired kidney function compared to controls. However, we observed no signs of increased subclinical atherosclerosis inwomenwith POI. Additional studies are required to identify specific determinants of long-term CVD risk in women with POI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available